Asset
Detalimogene Voraplasmid
enGene Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04752722 | phase1_2 | recruiting | 2021-04-22 | 2028-04-30 | enGene, Inc. | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve |
FDA applications (0)
This company has no applications containing this asset.